VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page on StockTitan.net provides comprehensive access to Vir Biotechnology (VIR) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, enhanced with AI-generated summaries and sentiment analysis. The platform helps investors track material events, financial disclosures, clinical program updates, and collaborations. The most recent filing highlighted is an 8-K from July 24, 2025, detailing the initiation of a first-in-human study for VIR-5525, an investigational T-cell engager for EGFR-expressing tumors.
VIR (NASDAQ: VIR) Form 144 shows 72,559-share sale after vesting
Vir Biotechnology, Inc. (NASDAQ: VIR) filed a Form 144 disclosing a proposed sale of 72,559 shares of common stock, which is tied to a restricted stock vesting event on April 6, 2026. The filing also details prior insider dispositions by Marianne De Backer, including sales of 19,039 shares on February 23, 2026, and 14,762 shares on February 24, 2026. Fidelity Brokerage Services LLC is listed as the broker for the proposed sale.
Evercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation
Evercore ISI Group has initiated coverage on Vir Biotechnology (VIR) with an "Outperform" rating. This new coverage suggests a positive outlook from the analytical firm regarding Vir Biotechnology's future performance.
VIR Earning Date, Earning Analysis and Earning Prediction
This article provides an in-depth analysis of Vir Biotechnology Inc. (VIR) earnings, including historical performance, future forecasts, and the impact of earnings reports on stock price. It details recent quarterly results, upcoming analyst predictions for Q1 2026, and the correlation between earnings forecast revisions and stock price movements, while also touching on investor sentiment from Q4 2025.
Evercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation
Evercore ISI Group has initiated coverage of Vir Biotechnology (VIR) with an "Outperform" rating. This new coverage suggests a positive outlook on the company's stock from the investment firm.
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR)
Vicki Sato, a Director at Vir Biotechnology Inc (VIR), sold 22,000 shares of the company on April 1, 2026, bringing her total ownership to 1,100,391 shares. Over the past year, Sato has sold 240,377 shares with no purchases, contributing to a total of 39 insider sells and no buys for VIR. The stock is currently trading at $9.07, and with a GF Value of $11.08, it is considered modestly undervalued.
Vir Biotechnology (NASDAQ:VIR) Director Sells $199,540.00 in Stock
Vir Biotechnology Director Vicki Sato sold 22,000 shares of the company's stock on April 1st for a total of $199,540.00, reducing her stake by 1.96%. The company's stock traded up by $0.08 to $9.10, with a market cap of $1.27 billion. Analysts maintain a "Moderate Buy" rating with an average target price of $20.44 for VIR.
Vir Biotechnology director Sato sells $199k in shares
Vir Biotechnology director Vicki L. Sato sold 22,000 shares of common stock for $199,616 as part of a pre-arranged trading plan. This insider sale follows a 59% return on VIR shares over the last six months, with analysts maintaining an optimistic outlook and price targets ranging from $17 to $30. The company recently completed a public offering raising $172.5 million and has strategic partnerships with Astellas Pharma.
Vir Biotechnology (VIR) director sells 22,000 shares in open market
Vir Biotechnology director Vicki L. Sato sold 22,000 shares of common stock at a weighted average price of $9.0735 per share on April 1, 2026, under a pre-set Rule 10b5-1 trading plan. After this open-market transaction, Sato directly holds 1,100,391 shares of the company's common stock. This sale, detailed in a Form 4 SEC filing, represents a moderate impact with a negative sentiment, reflecting routine portfolio activity rather than a new stock issuance.
Vir Biotechnology director Sato sells $199k in shares
Vir Biotechnology director Vicki L. Sato sold 22,000 shares of common stock for approximately $199,616, under a pre-arranged trading plan. This transaction occurred amidst a 59% return for VIR shares over the past six months, with analysts maintaining an optimistic outlook. The company recently completed a public offering raising $172.5 million and has strategic partnerships with Astellas Pharma.
Vir Biotechnology (VIR) price target increased by 26.10% to 20.74
This article reports a significant increase in the price target for Vir Biotechnology (VIR), with analysts raising it by 26.10% to 20.74. This adjustment signals a positive outlook for the company's stock performance.
Vir Biotechnology (VIR) price target increased by 26.10% to 20.74
Vir Biotechnology (VIR) recently saw its price target increased by 26.10% to $20.74. This adjustment reflects updated analyst sentiment regarding the company's future stock performance.
Vanguard affiliates disaggregate holdings; VIR shows 0% ownership (VIR)
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0% beneficial ownership in Vir Biotechnology Inc. (VIR) after an internal realignment on January 12, 2026. This adjustment reflects a change in reporting responsibility rather than an economic disposition, as certain subsidiaries will now report their holdings separately in reliance on SEC Release No. 34-39538. Investors should monitor future filings from Vanguard's affiliates for their separate positions.
Vir Biotechnology (VIR) price target increased by 26.10% to 20.74
The article reports that the price target for Vir Biotechnology (VIR) has been increased by 26.10%, reaching $20.74. No further details are provided regarding the reasons for this adjustment or the firm responsible for the target increase.
VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Vir Biotechnology (VIR) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. It features AI-generated summaries of key filings, such as a Q3 2025 earnings report and several insider sales by executives and affiliates of SoftBank Vision Fund. The page is designed to help investors track the company's financial position, clinical programs, and significant business updates in real-time.
Why did Vir Biotechnology stock surge 60% after-hours today?
This article briefly notes that Vir Biotechnology stock surged 60% in after-hours trading. However, the provided content is empty and does not explain the reasons behind this significant stock movement.
Vir Biotechnology (VIR) accounting chief sells 7,711 shares under plan
Vir Biotechnology's Senior Vice President and Chief Accounting Officer, Brent Sabatini, sold 7,711 shares of common stock at $9.12 per share on March 23, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on December 19, 2025. Following the sale, Sabatini directly holds 61,902 shares of Vir Biotechnology common stock.
Vir Biotechnology (NASDAQ:VIR) CAO Sells $70,324.32 in Stock
Vir Biotechnology's Chief Accounting Officer, Brent Sabatini, sold 7,711 shares of the company's stock for $70,324.32 on March 23rd, reducing his stake by 11.08%. Despite the sale, Vir Biotechnology (NASDAQ:VIR) reported an earnings beat and significant revenue growth, though the company remains unprofitable. Analysts maintain a "Moderate Buy" rating with an average target price of $20.44.
Vir Biotechnology prices $150M stock offering
This article reports that Vir Biotechnology has priced a public offering of its common stock and pre-funded warrants, aiming to raise $150 million. The offering includes 14,000,000 shares of common stock at $10.00 each and 1,000,000 pre-funded warrants at $9.99 each. The closing of the offering is anticipated on March 27, 2026, subject to customary conditions, with financial details and underwriters also specified.
VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Vir Biotechnology, Inc. (VIR) SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed company information and AI-generated summaries. Recent filings highlight a $200 million stock offering, significant collaboration and licensing agreements with Astellas, Norgine, and Sanofi totaling hundreds of millions in upfront payments and potential milestones, and updates on clinical programs for hepatitis delta and oncology. The company's financials for 2025 show $68.6 million in revenue and a net loss of $438.0 million, with cash expected to fund operations into Q2 2028.
Vir Biotechnology (VIR) CFO restructures 5,000 shares via family trust transfer
Vir Biotechnology's EVP & CFO Jason O'Byrne reported an internal restructuring of 5,000 shares of common stock. This transaction was a transfer without consideration for estate planning purposes, moving shares between his direct holdings and the O'Byrne Family Trust. The Form 4 filing indicates no open-market buying or selling but rather a reallocation of ownership, with O'Byrne now holding 160,115 shares directly and 2,500 indirectly.
VIR SEC Filings - Vir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Vir Biotechnology SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-generated summaries. It details recent material events such as a licensing agreement with Norgine Pharma UK Limited and financial updates, including cash balances and quarterly earnings. The platform aims to assist investors in tracking the company's clinical programs, collaborations, and financial position through real-time SEC filing integration.
Hudson Bay Capital Management LP Grows Position in Vir Biotechnology, Inc. $VIR
Hudson Bay Capital Management LP significantly increased its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 31% in the third quarter, bringing its total holding to 911,882 shares valued at approximately $5.21 million. This increase follows Vir Biotechnology's strong financial performance, where it beat quarterly EPS estimates and saw a substantial 417.8% year-over-year revenue growth. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $20.44, amidst recent upgrades and raised price targets.
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR) has received a consensus "Moderate Buy" rating from ten analyst firms, with an average one-year price target of $20.44. The company recently reported better-than-expected quarterly earnings, surpassing analyst estimates for EPS and revenue. Insider selling and institutional trading activity have also been noted, with several institutional investors increasing their stakes in the company.
Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation
Vir Biotechnology stock showed a pre-market gain of 0.2% in anticipation of its presentation at the Leerink conference. The article is very short, essentially noting this single event.
Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation
Vir Biotechnology (VIR) stock saw a 0.2% increase in pre-market trading ahead of its presentation at the Leerink Partners Global Healthcare Conference. Investors are focusing on potential updates regarding clinical timelines, especially for the VIR-5500 prostate cancer program's move into pivotal trials. The event is critical for the company as it aims to shift its narrative from COVID-19 to oncology and infectious disease, while reinforcing its cash runway into Q2 2028.
Marianne De Backer takes president role at Vir (NASDAQ: VIR)
Vir Biotechnology, Inc. announced that its CEO, Marianne De Backer, M.Sc., Ph.D., MBA, has also been appointed to the position of President, effective March 4, 2026. She will now serve as CEO, principal executive officer, and President. The company specified that there are no special arrangements, family relationships with directors or executive officers, or related-party transactions connected with this appointment.
Vir Biotechnology Names CEO Marianne De Backer as President
Vir Biotechnology has appointed CEO Marianne De Backer to the additional role of President, consolidating executive leadership. The company emphasized that this move involves no special arrangements or conflicts of interest, reinforcing standard governance. Analysts currently rate VIR stock as a Buy with a $20.00 price target, while TipRanks’ AI Analyst, Spark, deems it Neutral due to weak fundamentals balanced by strong forward-looking catalysts.
Vir Biotechnology Names CEO Marianne De Backer as President
Vir Biotechnology announced on March 4, 2026, the appointment of CEO Marianne De Backer to the additional role of President, consolidating executive leadership. This move aims to streamline decision-making and reinforce strategic continuity, with the company emphasizing no conflicts of interest. Analysts currently rate VIR stock as a Buy with a $20.00 price target, despite weak fundamentals showing ongoing losses, balanced by strong forward-looking catalysts like a major partnership and promising clinical signals.
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment.
Vir Biotechnology, Inc. has announced that Marianne De Backer will assume the role of President while continuing as Chief Executive Officer, effective March 4, 2026. This move aims to integrate the company's leadership and strengthen strategic execution. Analysts suggest this centralization of responsibilities could accelerate decision-making processes in the competitive biotechnology industry.
Vir Biotechnology Names CEO Marianne De Backer as President
Vir Biotechnology announced the appointment of its CEO, Marianne De Backer, to the additional role of President as of March 4, 2026. This move streamlines leadership by combining the CEO and President roles, emphasizing good governance with no conflicts of interest. The company aims to reassure investors about its transparent leadership structure, while analysts currently hold a Buy rating on VIR stock with a $20.00 price target.
Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026 - SEC filing
Vir Biotechnology announced the appointment of Marianne De Backer as president, in addition to her role as CEO, effective March 4, 2026. This information was disclosed in an SEC filing. The company focuses on developing treatments for serious infectious diseases and other conditions.
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright has increased its price target for Vir Biotechnology (NASDAQ:VIR) to $20 from $15, reiterating a "buy" rating and suggesting a 124% upside. The company recently surpassed earnings expectations, reporting a loss of ($0.31) per share against an anticipated ($0.42), and revenue of $64.07 million, a significant 417.8% year-over-year increase. Despite insider selling, institutional investors hold a substantial portion of the stock.
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment.
Vir Biotechnology, Inc. announced that Marianne De Backer will assume the role of President, effective March 4, 2026, while continuing as CEO. This appointment aims to streamline leadership and enhance strategic execution, especially given her background in driving innovation in infectious disease treatment. Analysts suggest this centralization of responsibilities could accelerate decision-making in the competitive biotech industry.
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares
Vir Biotechnology Director Vicki Sato sold 22,000 shares of the company's stock on March 2nd at an average price of $9.51, totaling $209,220. This sale reduced her ownership by 1.92%. Despite the insider sale, Vir Biotechnology recently reported better-than-expected quarterly earnings and revenue, and analysts maintain a "Moderate Buy" consensus rating with a target price of $19.89.
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR)
Vicki Sato, a Director at Vir Biotechnology Inc (VIR), sold 22,000 shares of the company on March 2, 2026, reducing her holdings to 1,122,391 shares. This transaction follows a pattern of insider selling at Vir Biotechnology, with 37 insider sells and 0 buys over the past year. Despite the insider selling, Vir Biotechnology's stock, trading at $9.51, is considered modestly undervalued with a price-to-GF-Value ratio of 0.85.
22,000 Vir Biotechnology (VIR) shares sold under 10b5-1 plan
Vir Biotechnology director Vicki L. Sato reported selling 22,000 shares of common stock on March 2, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted average prices of $9.5039 and $9.98 per share. Following these transactions, Sato directly owns 1,122,391 shares of Vir Biotechnology common stock.
Vir Biotechnology closes $172.5 million public offering of common stock
Vir Biotechnology Inc. has successfully completed a public offering of its common stock, raising approximately $172.5 million in gross proceeds. The offering included the exercise in full of the underwriters' 30-day option, with shares sold at $8.50 each. This capital raise follows a period of significant share price appreciation and comes amidst analyst upgrades for the company.
Vir Biotechnology Raises Capital Through Public Stock Offering
Vir Biotechnology (VIR) successfully raised approximately $172.5 million gross through a public offering of common stock, which closed on February 27, 2026. The biopharmaceutical company sold over 20 million shares at $8.50 each to support its infectious disease-focused operations. Despite weak financial performance and ongoing losses, an analyst has rated the stock as a Hold with a $9.50 price target.
Vir Biotechnology completes $172.5M follow-on offering, issues 20.29M shares
Vir Biotechnology completed a follow-on offering, issuing 20,294,117 shares and raising approximately $172.5 million gross. The offering, which closed on February 27, 2026, included the full exercise of the underwriters' 30-day option for an additional 2,647,058 shares. The proceeds are reported before deducting underwriting discounts, commissions, and offering expenses.
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC Filing - Form 8-K
Vir Biotechnology, Inc. has announced the completion of a public offering of common stock, raising approximately $172.5 million in gross proceeds. The company sold over 20 million shares, including additional shares purchased by underwriters, at $8.50 per share. This capital infusion, detailed in a Form 8-K filing, significantly strengthens the company's cash position but may lead to dilution for existing shareholders.
VIR Financials: Income Statement, Balance Sheet & Cash Flow
This article provides an in-depth financial overview of Vir Biotechnology, Inc. (VIR) based on its income statement, balance sheet, and cash flow statement for fiscal year 2025. It highlights key metrics such as revenue, EBITDA, net income, and various financial ratios, also offering an assessment of the company's financial health, which is rated as weak with a Piotroski F-Score of 3/9. The company reported a revenue decline and negative net income, but strong liquidity and low leverage.
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity
Vir Biotechnology, Inc.'s Senior Vice President and Chief Accounting Officer, Brent Sabatini, reported an automatic sale of 1,430 shares of common stock. This transaction, executed under a Rule 10b5-1 plan, was to cover tax withholding on vested restricted stock units at an average price of $9.5326 per share. Following this non-discretionary sale, Sabatini directly holds 69,613 shares.
Earnings call transcript: Vir Biotechnology beats Q4 2025 earnings expectations
Vir Biotechnology (VIR) exceeded Q4 2025 earnings and revenue expectations, leading to a slight stock increase after the announcement. The company reported an EPS of -$0.31 against a forecast of -$0.54 and revenue of $64.07 million, significantly higher than the $1.42 million forecast. This strong performance is attributed to strategic cost reductions and a new collaboration with Astellas Pharma for their VIR-5500 oncology program, which also showed promising Phase I data for metastatic castration-resistant prostate cancer.
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares
Vir Biotechnology EVP Verneuil Vanina De recently sold 3,117 shares of the company's stock, valued at $29,705.01, reducing her position by 2.40%. This sale is part of broader clustered insider selling by multiple executives between February 23-25, 2026. Despite positive news like a Q4 earnings beat, a significant revenue surge, and a new collaboration with Astellas, the stock traded down 6.8%, partly due to a dilutive public offering of 17.65 million shares.
Leerink Maintains Outperform on Vir Biotechnology, Inc. (VIR) Feb 2026
Leerink Partners has maintained its "Outperform" rating on Vir Biotechnology, Inc. (VIR) and raised its price target to $20. This decision reflects Leerink's continued confidence in the company's late-stage programs and future cash flows, despite recent financing activities. While the market reaction was modest, investors are advised to monitor clinical milestones and collaboration updates.
Vir Biotechnology to Participate in Upcoming Investor Conferences
Vir Biotechnology, Inc. announced its participation in three upcoming investor conferences in March. CEO Marianne De Backer will hold fireside chats at the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. Management will also be available for one-on-one meetings at the Barclays 28th Annual Global Healthcare Conference, with live webcasts of fireside chats available online.
Vir Biotechnology (NASDAQ: VIR) plans $141.1M stock sale
Vir Biotechnology announced a public offering of 17,647,059 shares of common stock at $8.50 per share, aiming to raise approximately $141.1 million in net proceeds, or up to $162.3 million if underwriters fully exercise their 30-day option for additional shares. The offering is underwritten by Goldman Sachs, Leerink Partners, Evercore, and Barclays, and is expected to close on February 27, 2026. This financial move increases the company's capital but could dilute existing shareholder value.
Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock
Latham & Watkins LLP advised the underwriters in Vir Biotechnology, Inc.'s public offering of 17,647,058 shares of common stock at US$8.50 per share, aiming to raise US$150 million. The clinical-stage biopharmaceutical company granted underwriters a 30-day option to purchase additional shares. The offering's closing is anticipated on February 27, 2026.
Vir Biotechnology to Participate in Upcoming March 2026 Investor Conferences
Vir Biotechnology, Inc. announced its participation in three investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference. CEO Marianne De Backer will participate in fireside chats at the first two events, and management will be available for one-on-one meetings at the Barclays conference. Live webcasts of the fireside chats will be available on the company's investor relations website.
